peptides tb 500 and bpc 157 BPC-157 + TB-500 Stack | 5/5mg & 10/10mg BPC-157 & TB-500 Blend 10mg
Description
With regard to tumor characteristics, 81% had Stage IV disease, 73% had non-squamous NSCLC and 27% had squamous NSCLC
Im a participant in the Astrazeneca Phase III trial
Sign in to save Potential benefits Tissue-repair research Unlike many pharmaceutical options, preclinical studies of BPC157 report broad tissue-repair activity without evidence of immune suppression
Please consult your doctor regarding use in pregnant females
